PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.26%
Cash & equivalents declining -8.26% while Biotechnology shows -6.42% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-8.26%
Near the Biotechnology median of -8.10% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Near the Biotechnology median of -8.55%. Charlie Munger sees typical short-term asset management among peers.
-11.00%
PP&E growth ≥ 1.5x the Biotechnology median of -3.99%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.61%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.27%
≥ 1.5x the Biotechnology median of -1.98%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
1.25-1.5x Biotechnology median of -6.31%. Mohnish Pabrai might see above-average growth. Check if financed sensibly.
18.31%
Payables growth above 1.5x Biotechnology median of 8.49%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.93%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Below half Biotechnology median of -1.84%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Below half Biotechnology median of -1.48%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-1.76%
0.5-0.75x Biotechnology median of -3.11%. Guy Spier is cautious about weaker retention vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
≥ 1.5x Biotechnology median of -7.69%. Joel Greenblatt sees stronger equity growth vs. peers.
-8.20%
1.25-1.5x Biotechnology median of -6.15%. Mohnish Pabrai notes above-average growth in liabilities + equity.
0.61%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-9.98%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
8.22%
Above 1.5x Biotechnology median 5.23%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.